WuXi XDC Cayman Inc (HK: 2268), a China-based global CRDMO (Contract Research, Development, and Manufacturing Organisation) specialising in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), announced on Thursday that it has been recognised as the winner of the 'Best CDMO' at the World ADC Awards 2024.
The company is being honoured for the second consecutive year.
The firm has been recognised at the World ADC Awards for the past three years, including being named the winner of the 'Best CDMO' in 2023 and 'Best CMO Runner-up' in 2022. In 2024, the firm was also shortlisted for 'Best ADC Platform Technology' and 'Best CRO'.
Dr Jimmy Li, WuXi XDC CEO, said: "Winning the prestigious award at the World ADC is a tremendous honour for WuXi XDC and a reflection of our team's relentless dedication to innovation and excellence. The recognition underscores the significant trust our clients place in us. Receiving the winner of the 'Best CDMO' award for two consecutive years highlights the consistency of our efforts and our position as a global leader in the ADC industry. WuXi XDC's mission is to accelerate and transform the discovery, development and manufacturing of bioconjugates through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. We will strive to provide our clients with state-of-the-art technologies and integrated solutions to contribute to the global healthcare industry."
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
Fusion Antibodies secures USD460,000 in follow-on contracts with US biotechnology client
INOVIO to begin rolling submission of BLA for INO-3107
ZYUS Life Sciences begins Phase 2a cancer pain trial with first patient enrolled
Curasight secures approval for phase 1 trial of uTREAT in glioblastoma patients
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
BioArctic and Novartis sign an option, collaboration and license agreement
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Innovent Biologics receives approval over squamous cell lung cancer study
Cambrex announces expansion of peptide manufacturing capabilities in Waltham, Massachusetts
Tyra Biosciences doses first child in dabogratinib Phase 2 achondroplasia clinical study